Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Potential mechanisms for poor prognosis in CD5+ DLBCL

Publish date:: August 17, 2020

Key clinical point: Lenalidomide, BTK inhibitors, Bcl-2 inhibitors, and immune therapy, among others, present promising results in vitro.

Major finding: Potential mechanisms fall into two pathways: the CD5-mediated BCR-dependent pathway and the CD5-mediated BCR-independent pathway.

Study details: Review of the biology, mechanisms, and treatment approaches in de novo CD5+ DLBCL.

Disclosures: The study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Jiangxi province. The authors reported having no disclosures.

Citation:

Xu Y et al. Clinical Lymphoma Myeloma and Leukemia. 2020; doi.org/10.1016/j.clml.2020.05.003.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,